<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081653</url>
  </required_header>
  <id_info>
    <org_study_id>MA17903</org_study_id>
    <nct_id>NCT00081653</nct_id>
  </id_info>
  <brief_title>A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva</brief_title>
  <official_title>Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg
      or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed
      Bonviva study BM16549 (MOBILE study). Patients will receive Bonviva either 100mg po monthly,
      or 150mg po monthly. Patients will also receive daily supplementation with vitamin D and
      calcium. The anticipated time of study treatment is 2+ years, and the target sample size is
      500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Mean Lumbar Spine (L2 - L4) BMD</measure>
    <time_frame>Baseline and Months 12, 24 and 36</time_frame>
    <description>Absolute change from Baseline in mean BMD of the lumbar spine (L2 - L4) measured as grams per square centimeter (g/cm^2). This was baseline of Study MA17903 after two years of treatment in the core study (BM16549 [NCT00081653]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Percent (%) Change From Baseline in Mean Lumbar Spine (L2 - L4) Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline and Months 12, 24 and 36</time_frame>
    <description>BMD was measured by a single dual-energy X-ray absorptiometry (DXA) scan of the lumbar spine (BMD of at least 2 vertebrae [L2-L4] that were not fractured and not affected by osteoarthritis to such a degree that BMD measurement would be compromised) at the time of enrollment and at Months 12, 24 and 36. This was baseline of Study MA17903 after two years of treatment in the core study (BM16549 [NCT00081653]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Mean Total Hip BMD</measure>
    <time_frame>Baseline and 12, 24 and 36 months</time_frame>
    <description>BMD was measured by a single DXA scan of the hip. Scores between -1 and -2.5 indicate Osteopenia (thin bones). Less than -2.5 indicate Osteoporosis (porous bones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Percent Change From Baseline in Mean Total Hip BMD</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>BMD was measured by a single DXA scan of the hip. Scores between -1 and -2.5 indicate Osteopenia (thin bones). Less than -2.5 indicate Osteoporosis (porous bones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline of Trough Serum CTX</measure>
    <time_frame>Baseline, 6, 12, 24 and 36 months</time_frame>
    <description>CTX is a measure of bone resorption and is measured as ng/mL. Blood samples for the Month 6 values were collected 6 days after the 6-month dose; therefore, the Month 6 values are not true 'trough' values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Percent Change From Baseline of Trough Serum CTX</measure>
    <time_frame>Baseline, 6,12, 24 and 36 months</time_frame>
    <description>CTX is a measure of bone resorption and is measured as nanograms per milliliter (ng/mL). Blood samples for the Month 6 values were collected 6 days after the 6-month dose; therefore, the Month 6 values are not true 'trough' values.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">719</enrollment>
  <condition>Post-Menopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate [Bonviva/Boniva]</intervention_name>
    <description>150mg po monthly for 3 years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate [Bonviva/Boniva]</intervention_name>
    <description>100mg po monthly for 3 years</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  successful completion of Bonviva study BM16549, with at least 75% compliance;

          -  ambulatory.

        Exclusion Criteria:

          -  malignant disease diagnosed within the previous 12 years (except basal cell cancer
             that has been successfully removed);

          -  breast cancer diagnosed within the previous 22 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04026-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfuered</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obregon</city>
        <zip>85100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haugesund</city>
        <zip>5507</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavanger</city>
        <zip>4010</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.roche-trials.com/studyResultGet.action?studyResultNumber=MA17903</url>
    <description>Clinical Study Report Synopsis</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2004</study_first_submitted>
  <study_first_submitted_qc>April 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2004</study_first_posted>
  <results_first_submitted>December 22, 2008</results_first_submitted>
  <results_first_submitted_qc>June 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2009</results_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 31 centers over the period of 18 May 2004 to 28 November 2007.</recruitment_details>
      <pre_assignment_details>Eligible for the study were patients having completed Study BM16549 (NCT00081653) and who had complied with the monthly regimen for 75 percent (%) or more.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibandronate 100 Milligrams (mg)</title>
          <description>100 mg ibandronate oral (PO) monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
        </group>
        <group group_id="P2">
          <title>Ibandronate 150 mg</title>
          <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="358">Patients entering Study MA17903 from Study BM16549</participants>
                <participants group_id="P2" count="361">Patients entering Study MA17903 from Study BM16549</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="311">Completed 3 years of treatment</participants>
                <participants group_id="P2" count="324">Completed 3 years of treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Low bone mineral density</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bone loss</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant leaving country</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of bone mass</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent -To - Treat (ITT) population: All participants who were randomized into this study, received at least one dose of the trial medication, and had at least one follow-up efficacy data point (BMD or serum C-terminal peptide cross-links of Collagen Type I [CTX]).</population>
      <group_list>
        <group group_id="B1">
          <title>Ibandronate 100 mg</title>
          <description>100 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
        </group>
        <group group_id="B2">
          <title>Ibandronate 150 mg</title>
          <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="358"/>
            <count group_id="B2" value="361"/>
            <count group_id="B3" value="719"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="6.55"/>
                    <measurement group_id="B2" value="67.7" spread="6.8"/>
                    <measurement group_id="B3" value="67.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="719"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.87" spread="4.957"/>
                    <measurement group_id="B2" value="26.04" spread="3.976"/>
                    <measurement group_id="B3" value="25.96" spread="4.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian/White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Mean Total Hip BMD</title>
        <description>BMD was measured by a single DXA scan of the hip. Scores between -1 and -2.5 indicate Osteopenia (thin bones). Less than -2.5 indicate Osteoporosis (porous bones).</description>
        <time_frame>Baseline and 12, 24 and 36 months</time_frame>
        <population>ITT Population; n = number of participants analyzed for the given parameter at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 100 mg</title>
            <description>100 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg</title>
            <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Mean Total Hip BMD</title>
          <description>BMD was measured by a single DXA scan of the hip. Scores between -1 and -2.5 indicate Osteopenia (thin bones). Less than -2.5 indicate Osteoporosis (porous bones).</description>
          <population>ITT Population; n = number of participants analyzed for the given parameter at the specified visit.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=345,348)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7680" spread="0.1093"/>
                    <measurement group_id="O2" value="0.7862" spread="0.1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=347,346)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7669" spread="0.1097"/>
                    <measurement group_id="O2" value="0.7888" spread="0.1116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 (n=344,345)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0004" spread="0.0204"/>
                    <measurement group_id="O2" value="0.0025" spread="0.0200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=322,336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7686" spread="0.1104"/>
                    <measurement group_id="O2" value="0.7882" spread="0.1124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=319,335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0010" spread="0.0227"/>
                    <measurement group_id="O2" value="0.0031" spread="0.0214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=301,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7663" spread="0.1133"/>
                    <measurement group_id="O2" value="0.7834" spread="0.1128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 36 (n=298,320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0061" spread="0.0254"/>
                    <measurement group_id="O2" value="-0.0030" spread="0.0252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Percent Change From Baseline in Mean Total Hip BMD</title>
        <description>BMD was measured by a single DXA scan of the hip. Scores between -1 and -2.5 indicate Osteopenia (thin bones). Less than -2.5 indicate Osteoporosis (porous bones).</description>
        <time_frame>Baseline, 12, 24 and 36 months</time_frame>
        <population>ITT Population; n = number of participants analyzed for the given parameter at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 100 mg</title>
            <description>100 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg</title>
            <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent Change From Baseline in Mean Total Hip BMD</title>
          <description>BMD was measured by a single DXA scan of the hip. Scores between -1 and -2.5 indicate Osteopenia (thin bones). Less than -2.5 indicate Osteoporosis (porous bones).</description>
          <population>ITT Population; n = number of participants analyzed for the given parameter at the specified visit.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Month 12 (n=344,345)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0169" spread="2.8582"/>
                    <measurement group_id="O2" value="0.3459" spread="2.5849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=319,335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1092" spread="3.1040"/>
                    <measurement group_id="O2" value="0.4378" spread="2.8062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 36 (n=298,320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8045" spread="3.3448"/>
                    <measurement group_id="O2" value="-0.3496" spread="3.3254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline of Trough Serum CTX</title>
        <description>CTX is a measure of bone resorption and is measured as ng/mL. Blood samples for the Month 6 values were collected 6 days after the 6-month dose; therefore, the Month 6 values are not true 'trough' values.</description>
        <time_frame>Baseline, 6, 12, 24 and 36 months</time_frame>
        <population>ITT population; n = number of participants analyzed for the given parameter at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 100 mg</title>
            <description>100 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg</title>
            <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline of Trough Serum CTX</title>
          <description>CTX is a measure of bone resorption and is measured as ng/mL. Blood samples for the Month 6 values were collected 6 days after the 6-month dose; therefore, the Month 6 values are not true 'trough' values.</description>
          <population>ITT population; n = number of participants analyzed for the given parameter at the specified visit.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 56,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.232" spread="0.1520"/>
                    <measurement group_id="O2" value="0.219" spread="0.1799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 Postdose (n=56,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.176" spread="0.1826"/>
                    <measurement group_id="O2" value="0.126" spread="0.1222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 6 Postdose (n=55,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.1307"/>
                    <measurement group_id="O2" value="-0.093" spread="0.1510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=57,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.279" spread="0.1617"/>
                    <measurement group_id="O2" value="0.208" spread="0.1073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 (n=56,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.1303"/>
                    <measurement group_id="O2" value="-0.011" spread="0.1406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=54,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.309" spread="0.1406"/>
                    <measurement group_id="O2" value="0.266" spread="0.1548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=53,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" spread="0.1203"/>
                    <measurement group_id="O2" value="0.048" spread="0.1607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=51,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" spread="0.1805"/>
                    <measurement group_id="O2" value="0.380" spread="0.2036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 (n=50,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.205" spread="0.1396"/>
                    <measurement group_id="O2" value="0.174" spread="0.1549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Mean Lumbar Spine (L2 - L4) BMD</title>
        <description>Absolute change from Baseline in mean BMD of the lumbar spine (L2 - L4) measured as grams per square centimeter (g/cm^2). This was baseline of Study MA17903 after two years of treatment in the core study (BM16549 [NCT00081653]).</description>
        <time_frame>Baseline and Months 12, 24 and 36</time_frame>
        <population>ITT population; number (n) equals (=) number of participants analyzed at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 100 mg</title>
            <description>100 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg</title>
            <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Mean Lumbar Spine (L2 - L4) BMD</title>
          <description>Absolute change from Baseline in mean BMD of the lumbar spine (L2 - L4) measured as grams per square centimeter (g/cm^2). This was baseline of Study MA17903 after two years of treatment in the core study (BM16549 [NCT00081653]).</description>
          <population>ITT population; number (n) equals (=) number of participants analyzed at the specified visit.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=347,346)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7916" spread="0.0814"/>
                    <measurement group_id="O2" value="0.7977" spread="0.0791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=347,346)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7977" spread="0.0831"/>
                    <measurement group_id="O2" value="0.8069" spread="0.0819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 (n=346,343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0061" spread="0.0293"/>
                    <measurement group_id="O2" value="0.0097" spread="0.0289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=323,336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8048" spread="0.0861"/>
                    <measurement group_id="O2" value="0.8111" spread="0.0852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=322,333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0131" spread="0.0332"/>
                    <measurement group_id="O2" value="0.0140" spread="0.0356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=308,320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8090" spread="0.0916"/>
                    <measurement group_id="O2" value="0.8155" spread="0.0892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 36 (n=307, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0172" spread="0.0382"/>
                    <measurement group_id="O2" value="0.0194" spread="0.0383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Percent (%) Change From Baseline in Mean Lumbar Spine (L2 - L4) Bone Mineral Density (BMD)</title>
        <description>BMD was measured by a single dual-energy X-ray absorptiometry (DXA) scan of the lumbar spine (BMD of at least 2 vertebrae [L2-L4] that were not fractured and not affected by osteoarthritis to such a degree that BMD measurement would be compromised) at the time of enrollment and at Months 12, 24 and 36. This was baseline of Study MA17903 after two years of treatment in the core study (BM16549 [NCT00081653]).</description>
        <time_frame>Baseline and Months 12, 24 and 36</time_frame>
        <population>ITT population: n = number of participants analyzed for the given parameter at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 100 mg</title>
            <description>100 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg</title>
            <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent (%) Change From Baseline in Mean Lumbar Spine (L2 - L4) Bone Mineral Density (BMD)</title>
          <description>BMD was measured by a single dual-energy X-ray absorptiometry (DXA) scan of the lumbar spine (BMD of at least 2 vertebrae [L2-L4] that were not fractured and not affected by osteoarthritis to such a degree that BMD measurement would be compromised) at the time of enrollment and at Months 12, 24 and 36. This was baseline of Study MA17903 after two years of treatment in the core study (BM16549 [NCT00081653]).</description>
          <population>ITT population: n = number of participants analyzed for the given parameter at the specified visit.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Month 12 (n=346,343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8348" spread="3.8118"/>
                    <measurement group_id="O2" value="1.2550" spread="3.6402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=322,333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6921" spread="4.2385"/>
                    <measurement group_id="O2" value="1.7865" spread="4.5058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 36 (n=307,318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1794" spread="4.9176"/>
                    <measurement group_id="O2" value="2.4322" spread="4.8146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Percent Change From Baseline of Trough Serum CTX</title>
        <description>CTX is a measure of bone resorption and is measured as nanograms per milliliter (ng/mL). Blood samples for the Month 6 values were collected 6 days after the 6-month dose; therefore, the Month 6 values are not true 'trough' values.</description>
        <time_frame>Baseline, 6,12, 24 and 36 months</time_frame>
        <population>ITT population; n = number of participants analyzed for the given parameter at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 100 mg</title>
            <description>100 mg ibandgronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg</title>
            <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent Change From Baseline of Trough Serum CTX</title>
          <description>CTX is a measure of bone resorption and is measured as nanograms per milliliter (ng/mL). Blood samples for the Month 6 values were collected 6 days after the 6-month dose; therefore, the Month 6 values are not true 'trough' values.</description>
          <population>ITT population; n = number of participants analyzed for the given parameter at the specified visit.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=56,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.232" spread="0.1520"/>
                    <measurement group_id="O2" value="0.219" spread="0.1799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 Postdose (n=56, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.176" spread="0.1826"/>
                    <measurement group_id="O2" value="33.109" spread="40.3544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 6 Postdose (n=55,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.622" spread="43.4212"/>
                    <measurement group_id="O2" value="-33.109" spread="40.3544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=57,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.279" spread="0.1617"/>
                    <measurement group_id="O2" value="0.208" spread="0.1073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 (n=56,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.121" spread="58.9832"/>
                    <measurement group_id="O2" value="25.125" spread="86.5607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=54,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.309" spread="0.1406"/>
                    <measurement group_id="O2" value="0.266" spread="0.1548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=53,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.657" spread="65.3128"/>
                    <measurement group_id="O2" value="53.704" spread="74.9810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (51,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" spread="0.1805"/>
                    <measurement group_id="O2" value="0.380" spread="0.2036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 36 (n=50,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.106" spread="97.9878"/>
                    <measurement group_id="O2" value="138.502" spread="125.7590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from the date of informed consent until 15 days after the final visit at 36 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibandronate 100 mg</title>
          <description>100 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 150 mg tablet)</description>
        </group>
        <group group_id="E2">
          <title>Ibandronate 150 mg</title>
          <description>150 mg ibandronate PO monthly and monthly oral placebo (corresponding to the 100 mg tablet)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Cardiac fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fibrous dysplasia of bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Keratoconus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Tetanus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Central obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Medullary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Peritoneal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Signet-ring cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Vaginal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus management</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="358"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="361"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Study Director</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>+1 973 235 5000</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

